Elovl6の欠損は膵β細胞量とインスリン分泌能を増加させることによりdb/db マウスの糖尿病発症を抑制する by 赵 会 & ZHAO HUI
Elovl6 deficiency prevents diabetes in db/db
mice by increasing β-cell mass and insulin
secretory capacity
著者 ? 会
発行年 2017
その他のタイトル Elovl6の欠損は膵β細胞量とインスリン分泌能を増
加させることによりdb/db マウスの糖尿病発症を抑
制する
学位授与大学 筑波大学 (University of Tsukuba)
学位授与年度 2017
報告番号 12102甲第8344号
URL http://hdl.handle.net/2241/00150013
-１ 
 
 
氏     名 赵 会 
学 位 の 種 類       EA 博士（医学） 
A学 位 記 番 号       EA 博甲第  8344  号 
A学位授与年月       EA 平成 29年 7月 25日 
A学位授与の要件       EA 学位規則第４条第１項該当 
A審 査 研 究 科       EA 人間総合科学研究科 
A学位論文題目       EA Elovl6 deficiency prevents diabetes in db/db mice by increasing 
β-cell mass and insulin secretory capacity 
（Elovl6 の欠損は膵β細胞量とインスリン分泌能を増加させること 
により db/db マウスの糖尿病発症を抑制する） 
A主 査       EA     筑波大学教授   大根田修  博士（医学）    
副 査       EA   筑波大学講師 酒井 俊  博士（医学）   
A副 査       EA   筑波大学講師 田原 聡子 博士（医学）  
A副 査       EA   筑波大学助教 西村 健  博士（医学） 
 
 
論文の要旨 
Abstract of thesis 
 
【背景・目的 Background/Purpose】 
   The elongation of very long-chain fatty acid (ELOVL) family member Elovl6 is a microsomal 
enzyme involved in the elongation of saturated and monounsaturated FAs with 12, 14, and 16 
carbons. Loss of Elovl6 function reduces stearate (C18:0) and oleate (C18:1n-9) levels and 
increases palmitate (C16:0) and palmitoleate (C16:1n-7) levels.  In the previous study, it has been 
reported that mice with the targeted disruption of Elovl6 (Elovl6−/−) were protected against the 
development of hepatic insulin resistance and deterioration of insulin secretory function of 
pancreatic β cells in animals fed a high-fat and high-sucrose diet, despite similar levels of 
hepatosteatosis and obesity between Elovl6-deficient and wild-type mice.These findings suggested 
that the vital role of alterations in FA composition by Elovl6 deficiency extended beyond lipid 
accumulation and impacted insulin sensitivity and β-cell function. The author speculated that Elovl6 
inhibition could be a potential therapeutic approach in type 2 diabetes (T2D) treatment. The author 
would like to investigate about following points: 
- To determine the effect of endogenous Elovl6 in leptin receptor –deficient db/db mice (db/db: 
Elovl6-/-) 
 
- To determine whether beta-cell function and islet inflammation could be altered by changes in 
cellular FAs regulated by Elovl6  
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【対象と方法 Material and methods】 
   Leprdb/+ (db/+) mice on a C57BL/KsJ background were purchased and the author crossed with 
Elovl6−/− mice (C57BL6J background) to obtain db/+;Elovl6+/− mice. db/+;Elovl6+/− mice were then 
crossed more than seven generations into the C57BL/KsJ background. Finally, double 
heterozygous male and female mice were bred to generate mice with the double mutation of Lepr 
and Elovl6 (db/db;Elovl6−/−). 
   Pancreases were excised, fixed in 10% neutrall buffered formalin, embedded in paraffin and cut 
into 4-micrometer-thick sections. The author stained the sections with antibodies to examine the 
expressions of proteins or BrdU antibody to check proliferative activity with secondary antibodies. 
   Isolation of islets from mice was performed by Ficoll-Conray density gradient centrifugation and 
hand picking. The author checked insulin secretion of these islet cells using ELISA kit. 
 
 【結果・考察 Results】 
1) The author found that both db/db and db/db: Elovl6-/- mice during 6-16 weeks old show gained 
body weight (BW) without any significant differences. The author also found that at 40 weeks of 
age, db/db mice exhibited diabetes and BW loss, whereas db/db: Elovl6-/- mice sustained a 
gain without hyperglycemia and hyperinsulinemia. 
2) The author found that in db/db: Elovl6-/- mice, increased secretin of insulin was observed by 
OGTT, whereas insulin sensitivity did not change compared to db/db mice by ITT. 
3) The author found that liver weight, heaptic triglyceride, total cholesterol, and alanine 
transaminase levels were higher in db/db: Elovl6-/- mice than db/db mice. And the author found 
the dramaric increase in lipid droplets in db/db: Elovl6-/- mice compared to db/db mice by 
histological analysis. 
4) The author did hepatic gene analysis and found that increased expression of glucokinase and 
stearoyl-CoA desaturase 1 and decreased expression of glucose-6-phosphase in db/db: 
Elovl6-/- mice compared to db/db mice. 
5) The author found that in db/db: Elovl6-/- mice, the number and size of islets were greater, 
resulting in enlarged size of islets and increased beta-cell mass compared to db/db mice.   
6) The author found that islet hyperplasia in db/db: Elovl6-/- mice was a consequence of 
increased proliferation and reduced apoptosis of beta-cells. 
7) The author found that insulin content was higher in db/db: Elovl6-/- mice than db/db mice. 
8) The author found that there was a marked reduction in oleate composition of db/db: Elovl6-/- 
islets compared to db/db islets. 
9) The author found that Elovl6 deficiency significantly decreased the expression of 
prionflammatory genes, such as CD68, TNF-alpha, IL-1beta, CCL2, CCR2, CCL21a, Glycam1, 
and Saa3 in both db/+ and db/db islets. 
10) The author found the cellular oleate content could be a determinant of Elovl6-mediated 
beta-cell function and the FA composition of islets in db/db: Elovl6-/- mice was favorable for the 
protection of beta-cells in db/db mice. 
 
審査の要旨 
 Abstract of assessment result 
 
【批評 General Comments】 
   The author clearly demonstrated that db/db:Elovl6−/− mice had improved glucose tolerance, 
enhanced GSIS, hyperinsulinemia, and markedly increased β-cell mass associated with increased 
proliferation and decreased apoptosis compared to db/db mice. In addition, the author clarified the 
molecular mechanisms underlying these phenotypic changes in db/db;Elovl6−/− mice, that involve 
decreased expression of islet proinflammatory genes and attenuated islet inflammation 
accompanied with decreased islet oleate and TG levels. Of note, the author’s findings indicated 
that Elovl6-mediated modulation of intracellular FA metabolism in β cells was essential in 
preventing the toxic effects of FAs and preserving proper β-cell function, suggesting that limiting 
Elovl6 expression in individuals during early diabetes or in those with metabolic syndrome might be 
beneficial for T2D prevention and treatment.  
 
-３ 
【最終試験の結果 Assessment】 
The final examination committee conducted a meeting as a final examination on May 31, 2017. 
The applicant provided an overview of dissertation, addressed questions and comments raised 
during Q&A session. All of the committee members reached a final decision that the applicant has 
passed the final examination.  
 
【結果 Conclusion】 
Therefore, the final examination committee approved that the applicant is qualified to be 
awarded Doctor of Philosophy in Medical Sciences. 
